Skip to main content
Fig. 6 | Alzheimer's Research & Therapy

Fig. 6

From: Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

Fig. 6

Cognitive Assessment Changes from Baseline Score. Cognitive assessments measured at Baseline, at Week 11 (1 week after the last treatment infusion), and at the end of the study (Week 22, or early termination), expressed as a change from baseline scores for each assessment scale. Top panels: individual subject plots. Dotted lines are subjects in Cohort 1 (1 × 109 cells), dashed lines are subjects in Cohort 2 (2 × 109 cells) and solid lines are subjects in Cohort 3 (4 × 109 cells). Subject 6 did not complete the Week 22 assessment. Bottom panels: medians with interquartile ranges

Back to article page